ECSP10010602A - Compuestos de anillo fusionados y uso de los mismos - Google Patents

Compuestos de anillo fusionados y uso de los mismos

Info

Publication number
ECSP10010602A
ECSP10010602A EC2010010602A ECSP10010602A ECSP10010602A EC SP10010602 A ECSP10010602 A EC SP10010602A EC 2010010602 A EC2010010602 A EC 2010010602A EC SP10010602 A ECSP10010602 A EC SP10010602A EC SP10010602 A ECSP10010602 A EC SP10010602A
Authority
EC
Ecuador
Prior art keywords
fusioned
same
ring compounds
provides
present
Prior art date
Application number
EC2010010602A
Other languages
English (en)
Inventor
Tsuneo Yasuma
Nobuyuki Takakura
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of ECSP10010602A publication Critical patent/ECSP10010602A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

La presente invención proporciona un activador de glucocinasa útil como un agente farmacéutico tal como un agente para la profilaxis o tratamiento de diabetes, obesidad y similares. La presente invención proporciona un activador de glucocinasa que contiene un compuesto representado por la fórmula (I): en donde cada símbolo se define en la especificación, o una sal del mismo o un profármaco del mismo.
EC2010010602A 2008-04-10 2010-11-10 Compuestos de anillo fusionados y uso de los mismos ECSP10010602A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008102691 2008-04-10

Publications (1)

Publication Number Publication Date
ECSP10010602A true ECSP10010602A (es) 2011-03-31

Family

ID=40671202

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010602A ECSP10010602A (es) 2008-04-10 2010-11-10 Compuestos de anillo fusionados y uso de los mismos

Country Status (35)

Country Link
US (1) US8673942B2 (es)
EP (1) EP2276760B1 (es)
JP (1) JP5528348B2 (es)
KR (1) KR20110002472A (es)
CN (1) CN102056924B (es)
AR (1) AR073609A1 (es)
AU (1) AU2009234666B2 (es)
BR (1) BRPI0910912A2 (es)
CA (1) CA2720686A1 (es)
CO (1) CO6321240A2 (es)
CR (1) CR11730A (es)
CY (1) CY1115247T1 (es)
DK (1) DK2276760T3 (es)
DO (1) DOP2010000301A (es)
EA (1) EA019640B1 (es)
EC (1) ECSP10010602A (es)
ES (1) ES2476265T3 (es)
GE (1) GEP20135846B (es)
HK (1) HK1152932A1 (es)
HR (1) HRP20140588T1 (es)
IL (1) IL208463A (es)
MA (1) MA32283B1 (es)
ME (1) ME01887B (es)
MX (1) MX2010011138A (es)
MY (1) MY152475A (es)
NZ (1) NZ588562A (es)
PE (1) PE20100734A1 (es)
PL (1) PL2276760T3 (es)
PT (1) PT2276760E (es)
RS (1) RS53378B (es)
SI (1) SI2276760T1 (es)
UA (1) UA104422C2 (es)
UY (1) UY32131A (es)
WO (1) WO2009125873A1 (es)
ZA (1) ZA201007682B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010076884A1 (ja) 2008-12-29 2010-07-08 武田薬品工業株式会社 新規縮合環化合物およびその用途
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014085486A2 (en) 2012-11-30 2014-06-05 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin d metabolites
US9453038B2 (en) 2012-12-17 2016-09-27 Merck Sharp & Dohme Corp. Glucokinase activator compounds, compositions containing such compounds, and methods of treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05505612A (ja) 1991-03-01 1993-08-19 ハー・ルンドベック・アクティーゼルスカブ 高血圧症及び末梢血管疾患の治療法
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
CN101103977A (zh) 2002-06-05 2008-01-16 株式会社医药分子设计研究所 糖尿病治疗药
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
WO2006089397A1 (en) 2005-02-22 2006-08-31 Gemin X Biotechnologies Inc. Methods for treating arthritis using triheterocyclic compounds
EP2308839B1 (en) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US7799820B2 (en) 2005-09-30 2010-09-21 Banyu Pharmaceutical Co., Ltd. 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions
KR101444486B1 (ko) 2006-10-19 2014-09-24 다케다 야쿠힌 고교 가부시키가이샤 인돌 화합물
JP5323834B2 (ja) 2007-08-17 2013-10-23 エルジー・ライフ・サイエンシーズ・リミテッド 細胞壊死阻害剤としてのインドール化合物
CN101896483B (zh) 2007-12-20 2013-11-20 株式会社Lg生命科学 葡糖激酶激活剂和包含其作为活性成分的药物组合物
JP5188583B2 (ja) * 2008-01-04 2013-04-24 エルジー・ライフ・サイエンシーズ・リミテッド 細胞、組織及び臓器保存効果を有するインドール及びインダゾール誘導体
WO2010076884A1 (ja) 2008-12-29 2010-07-08 武田薬品工業株式会社 新規縮合環化合物およびその用途

Also Published As

Publication number Publication date
JP5528348B2 (ja) 2014-06-25
IL208463A0 (en) 2010-12-30
ES2476265T3 (es) 2014-07-14
DK2276760T3 (da) 2014-05-26
EP2276760A1 (en) 2011-01-26
AU2009234666B2 (en) 2014-02-20
PL2276760T3 (pl) 2014-09-30
EP2276760B1 (en) 2014-04-09
UA104422C2 (uk) 2014-02-10
JP2011516403A (ja) 2011-05-26
BRPI0910912A2 (pt) 2015-08-11
PE20100734A1 (es) 2010-11-18
WO2009125873A1 (en) 2009-10-15
HK1152932A1 (en) 2012-03-16
DOP2010000301A (es) 2010-12-31
NZ588562A (en) 2012-07-27
CN102056924B (zh) 2014-05-21
KR20110002472A (ko) 2011-01-07
AU2009234666A1 (en) 2009-10-15
CN102056924A (zh) 2011-05-11
GEP20135846B (en) 2013-06-10
SI2276760T1 (sl) 2014-05-30
US20110098297A1 (en) 2011-04-28
RS53378B (en) 2014-10-31
ME01887B (me) 2014-12-20
MA32283B1 (fr) 2011-05-02
CR11730A (es) 2010-12-08
MX2010011138A (es) 2010-11-12
MY152475A (en) 2014-10-15
UY32131A (es) 2010-11-30
ZA201007682B (en) 2011-12-28
IL208463A (en) 2015-07-30
HRP20140588T1 (hr) 2014-08-01
PT2276760E (pt) 2014-05-28
EA019640B1 (ru) 2014-05-30
CY1115247T1 (el) 2017-01-04
US8673942B2 (en) 2014-03-18
CA2720686A1 (en) 2009-10-15
EA201071180A1 (ru) 2011-04-29
AR073609A1 (es) 2010-11-17
CO6321240A2 (es) 2011-09-20

Similar Documents

Publication Publication Date Title
ECSP10010602A (es) Compuestos de anillo fusionados y uso de los mismos
ECSP099330A (es) Compuesto de indol
CR10564A (es) Compuestos cíclicos fusionados
DOP2010000267A (es) Compuesto heterociclico
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
ECSP13012719A (es) Compuesto bicíclico
MY155317A (en) Benzene sulfonamide thiazole and oxazole compounds
CL2015002698A1 (es) Nuevos compuestos y composiciones para la inhibicion de fasn
ECSP12011573A (es) Compuestos tetracíclicos
UY33547A (es) COMPUESTOS QUÍMICOS Bcl-2 y Bcl-XL
CO6511251A2 (es) Compuestos quimicos
UY32494A (es) Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones
CL2007002890A1 (es) Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad.
CL2008003041A1 (es) Compuestos derivados de acido boronico, inhibidores de proteasoma; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
BR112012032087A2 (pt) composto, medicamento, e, uso de um composto
ECSP11011558A (es) Nuevos compuestos químicos.
AR081819A1 (es) Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades
CL2008003639A1 (es) Compuestos derivados de amida; composición farmacéutica que comprende a dicho compuesto; combinación farmacéutica; y uso del compuesto en el tratamiento del vih.
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
CL2011001026A1 (es) Uso de pimobedan para preparar un medicamento util en el tratamiento de cardiomiopatia hipertrofica en un gato.
CU20100063A7 (es) Benzotiazoles como moduladores del receptor de grelina
UY35685A (es) Compuestos de dióxido de amino tiazina bicíclicos puenteados como inhibidores de beta-secretasa y sus métodos de uso
BRPI0821116B8 (pt) composto, composição farmacêutica que o contem, uso deste e processo para a preparação do mesmo
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
CR11613A (es) Asociacion entre una sal de bis-tiazolio o uno de sus precursores y artemisinina o uno de sus derivados para el tratamiento del paludismo grave